(MENAFN - Arab News) More than 300 doctors from the kingdom attended the launch of a revolutionary new treatment for type 2 diabetes held in dubai over the weekend.
the launch of the product victoza (liraglutide) was announced by novo nordisk in dubai.
the medicine taken once daily at any fixed time irrespective of meals under prescription by specialist will change the course of the disease for better results and is available at stores throughout the kingdom.
'the launch of victoza is major news for saudi arabia" said vikrant shrotriya general manager of novo nordisk gulf. 'specialist in the kingdom will now have a therapy that targets the underlying problems of the disease inspiring a sense of control."
'saudi arabia has around around 3.6 million diabetics above the age of 20 while a similar number of people are pre-diabetic" he said.
diabetes is a dangerous condition and elevated blood sugar very often leads to the disease.
'victoza is a significant treatment option for patients with type 2 diabetes. it constitutes an important new addition to the portfolio which is designed to support our mission to defeat the deadly disease" he said.
'this is why we are proud to make victoza available to patients in the kingdom."
victoza provides excellent glycemic control and delays disease progression in type 2 diabetes patients while aiding lasting weight loss.
victoza works with the body to lower blood sugar levels by boosting the release of insulin only when needed. these unique benefits result in blood sugar control combined with a reduced risk of blood sugar levels dropping too low.
victoza marks a decisive step forward for people with type 2 diabetes many of whom are overweight. 'type 2 diabetes often coexists with other high-risk conditions such as high blood pressure high cholesterol and obesity which add to the cardiovascular risk" said waleed abdel fattah medical director of novo nordisk gulf.
'victoza provides the answer for people to control diabetes and reduce the risk factors that may lead to development of complications."